share_log

Benchmark Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

Benzinga ·  Oct 20, 2023 10:28

Benchmark analyst Robert Wasserman reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment